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New Roads, New Ruts
Lessons From Drug-Eluting Stent Restenosis*
Adnan Kastrati, MD, Robert Byrne, MB BCH
Munich, Germany
The Achilles’ heel of coronary stenting has long been the
occurrence of arterial renarrowing or restenosis in the
months after intervention (1). The advent of drug-eluting
stent (DES) therapy appeared initially to herald the eradi-
cation of in-stent restenosis and the culmination of inno-
vation in interventional cardiology. However, although this
technology has undoubtedly facilitated the expansion of
percutaneous intervention into domains formerly limited by
either unsatisfactorily high incidence or inacceptable conse-
quences of restenosis, the passage of time has shown us that
reports of the demise of coronary restenosis were perhaps
greatly exaggerated. Indeed, partly a victim of its own
success, the number of patients developing restenosis after
DES may be as high as 200,000 per annum in the U.S.
alone (2).
See page 155
From a pathophysiological standpoint, stent implantation
during percutaneous intervention largely negates the impact
of mechanical factors that contribute to restenosis: namely,
prolapse of disrupted plaque, elastic vessel recoil, and
constrictive arterial remodeling. Indeed restenosis within
bare-metal stents (BMS) is caused almost exclusively by
neointimal hyperplasia, an iatrogenic process characterized
by vascular smooth muscle hyperplasia and extracellular
matrix deposition (3,4). Whereas DES therapy successfully
inhibits neointimal hyperplasia across the spectrum of cor-
onary disease lesions and presentations, it does so at the
expense of a systematic delay in healing of the stented
arterial segment (5). One consequence is that the time
course of restenosis after DES is temporally right-shifted.
Indeed, numerous imaging studies have documented un-
equivocal evidence of late erosion of antirestenotic efficacy
(“late luminal creep”) beyond the 6- to 8-month window
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e has no relationships to disclose.during which BMS restenosis tended to have reached its
peak (6,7). Although the clinical impact of this late catch-up
appears low, there are important implications in the choice
of time point assessment in trials evaluating antirestenotic
efficacy and also for future stent design (with polymer-free
platforms perhaps immune from this phenomenon). Finally,
when it occurs, DES restenosis may be morphologically
somewhat distinct from restenosis after bare-metal stenting,
with a relatively cell-depleted neointima composed predom-
inantly of extracellular matrix, and perhaps an excess of de
novo in-stent atherosclerosis (1,8,9).
In this issue of JACC: Cardiovascular Interventions, Latib
et al. (10) report on 392 patients presenting with DES
restenosis who were managed with repeat percutaneous
intervention. In the past, the Milan group has contributed
significantly to our understanding of coronary restenosis,
and although the present report is subject to the typical
limitations imposed by an observational registry design, it
represents a relevant addition to literature concerning the
ever-increasing number of patients with DES restenosis. In
many respects, their article is an extension of the important
paper of Cosgrave et al. (11) from the same group, with the
advantage of an additional 3 years of patient enrollment and
an extension of follow-up from a median of 13 months out
to 3 years. So what are the lessons that we can distill from
the investigators’ observations and indeed from experiences
in general with DES restenosis over the last decade?
Lesson #1: In DES Treatment Failure,
the Pattern of Restenosis Is More Often Focal
Many studies have described a ratio of focal/nonfocal
restenosis after DES implantation of approximately two-
thirds/one-third (12–14). This is precisely the breakdown
observed in the present report (Fig. 1). In contrast, in BMS
restenosis, the ratio is of the order of 40%/60% (15). This
difference can be accounted for in at least 2 ways. First, the
high-efficacy inhibition of neointimal formation by DES
means that technical factors (e.g., mal-expansion or stent
fracture), which are associated with more focal-pattern
restenosis, play a relatively greater causative role. Second,
al-apposition may arguably have proportionately greater
mpact on restenosis after DES, as it may also hinder
ffective drug transfer to local tissue. In a similar vein,
lthough largely unstudied, it is conceivable that the abso-
ute incidence of stent fracture may be higher after DES
han after bare-metal stenting, consequent, hypothetically,
n enhanced local instability and altered arterial shear forces
econdary to low volume neointimal overgrowth. It is
nticipated that newer, more sophisticated intracoronary
maging modalities may shed further light on these mech-
nisms and facilitate more thorough classification of DES
estenosis (16).
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166Lesson #2: In DES Restenosis,
the Pattern Continues to Predict the Outcome
In BMS restenosis, the angiographic patterns of neointimal
overgrowth were shown to be an important prognostic
indicator (15). The current report re-emphasizes that in
DES restenosis this tenet also holds true. Latib et al. (10)
use a modified Mehran classification to divide restenosis
into 3 groups: focal, diffuse, and occlusive. Although the
rate of surveillance angiography is low, the rate of a second
restenosis increased progressively across the groups: from
29% (focal restenosis) to 46% (diffuse restenosis) to 66%
(occlusive restenosis). It should be acknowledged that this
trend did not hold true for clinical restenosis. Although the
rate of target lesion revascularization increased from 16.5%
for focal to 28% for diffuse, it dropped to 22% for patients
with occlusive restenosis. This discordance indicates that
chronic vessel occlusion in the setting of a second restenosis
is often accepted as a sign that a revascularization strategy
has failed, and in the present dataset, a significant number of
patients proceeded to a trial of medical therapy, at least
initially. Finally, the difficulty in correlating pattern of
restenosis with hard clinical events should be recognized;
after all, pattern classification is often accompanied by
repeat intervention in the same sitting, and as such, the
natural history of the index restenotic lesion is altered.
Lesson #3: Diabetes Mellitus–Associated
Relative Restenosis Risk Is Greatly Attenuated
With DES
Although the presence of diabetes mellitus conferred a clear
increased risk of BMS restenosis, the introduction of DES
seems to be associated with a leveling of the playing field in
Figure 1. Distribution of Morphological Patterns of Restenosis After
Bare-Metal and Drug-Eluting Stents
(A) Bare-metal stent(s); data from Mehran et al. (15). (B) Drug-eluting stent(s);
pooled data from Latib et al. (10) and Mehilli et al. (24).this respect. Indeed a number of large analyses from groupsin Seoul, Korea; Washington, DC; and our center in Munich,
Germany have shown similar rates of restenosis in patients
with and without diabetes (17–19). The current report
contains a signal that the same also holds true for the
treatment of DES restenosis (most often managed with
repeat DES implantation). The rate of recurrent restenosis
was comparable in diabetics versus nondiabetics (35.2% vs.
38.4%; p  0.65). Looking at the bigger picture, it seems
that the high efficacy of DES devices has greatly attenuated
the excess risk of restenosis in patients with diabetes.
Lesson #4: Event Rates After Treatment for
DES Restenosis Remain High
The overall rate of major adverse events at 3 years in the
present report (10) was not inconsiderable at 32.8%. This is
not out of step with findings from other reports (12–14) and
serves as a valuable reminder that in this disease subset,
there remains some distance to be traveled before either
patient or physician can be satisfied with treatment out-
comes. Furthermore, the overall rate of target lesion
revascularization at 3 years approaches 20%. Indeed, it
might be observed that DES restenosis is a more recal-
citrant disease process, with rather higher rates of target
lesion revascularization seen than after treatment of BMS
restenosis (20).
Lesson #5: The Optimal Management of
DES Restenosis Remains Unclear
Comparative treatment efficacy analysis in registry reporting
always entails considerable hazard due to the effects of
residual unmeasured confounding (21). In this respect,
although the investigators were careful to avoid direct
comparisons between outcomes of restenosis treated with
balloon angioplasty versus repeat DES therapy, their asser-
tion that “the treatment of DES restenosis with repeat DES
implantation appears to be associated with a reduction in
recurrent restenosis (without) impact on the risk of late stent
thrombosis” is perhaps the most tenuous of their findings.
Certainly, the rate of definite stent thrombosis (2 incident
cases [0.5%]) is indeed low, and this is certainly an encour-
aging safety signal. However, a registry report helps little in
defining the most effective management strategy for patients
with DES restenosis, and more randomized controlled trial
data are urgently required.
So what are the options available for treatment of DES
restenosis? First, as the predominant pattern of restenosis
within DES is focal, repeat catheter intervention is likely to
remain the mainstay of initial management. In this respect,
we believe that the principal options are: 1) plain balloon
angioplasty; 2) drug-eluting stenting; and 3) drug-coated
balloon dilation. It might also be commented that oral
therapy has not been investigated for DES restenosis.
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167Indeed the terrific success of DES led directly to the
extinction of this therapeutic newborn despite encouraging
clinical evidence (22,23). In addition, some colleagues might
add brachytherapy as a further treatment option. Without
entering into details about the strength of evidence in its
favor, the lack of enthusiasm for embracing this therapy is
not a sign of a bright future.
In respect of the 3 principal treatment options, certain
lessons learned from BMS restenosis likely hold true: by
virtue of a combination of high acute gain and low late loss,
repeat DES implantation may remain superior to the other
modalities listed. Furthermore, our experiences from the
ISAR-DESIRE-2 (Intracoronary Stenting and Angiographic
Results: Drug Eluting Stents for In-Stent Restenosis-2) study
lead us to believe that a strategy of implanting a DES eluting
the same class of drug as the failed initial DES or a switch to
DES eluting another drug type are similarly efficacious (24).
However, in light of encouraging data in BMS restenosis (25),
he role of drug-coated balloon therapy in this therapeutic
iche deserves further investigation. The hypothesized advan-
age is intuitive. The presence of an existing stent backbone
rom the index intervention continues to oppose arterial recoil
nd remodeling, whereas the brief local application of active
rug at the time of angioplasty may deliver durable inhibition
f neointimal regrowth. Along similar lines, the fact that
ultiple layers of stent do not offer any advantage in
estenosis prevention highlights further the pressing need
or an effective completely resorbable DES. Finally, against
his background, we hope that data from the ongoing ISAR-
ESIRE-3 trial—in which patients with limus-agent DES
estenosis are randomized to plain balloon angioplasty,
aclitaxel-eluting stent, or paclitaxel-coated balloon—will shed
ome further light on the management of patients with this
hallenging clinical condition.
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